Cadrenal Therapeutics up as blood disease drug gets FDA's fast-track tag

Cadrenal Therapeutics

23/01/2023 14:07

** Shares of Cadrenal Therapeutics  CVKD.  rise 92% to $8
before the bell, among biggest pct gainer across the U.S. stock
exchange
    ** The drug developer says the U.S. FDA has granted
fast-track designation to tecarfarin drug, which prevents blood
clots in patients suffering with certain kidney or heart
diseases
    ** Fast-track designation is granted by the FDA to
facilitate development and expedite the review of therapies with
potential to treat a serious condition where there is an unmet
medical need
    ** Cadrenal stock up ~60% since its IPO filing last week on
Jan 20
 (Reporting by Khushi Mandowara)
 ((Khushi.Mandowara@thomsonreuters.com;))